AC IMMUNE SA

ACIU13 Dec 2024
Healthcare
$2.93
-0.01 (-1.39%)
Lowest Today
$2.93
Highest Today
$2.93
Today’s Open
$2.93
Prev. Close
$2.99
52 Week High
$5.14
52 Week Low
$2.25
To Invest in AC IMMUNE SA

AC IMMUNE SA

Healthcare
ACIU13 Dec 2024
-0.01 (-1.39%)
1M
3M
6M
1Y
5Y
Low
$2.93
Day’s Range
High
$2.93
2.93
52 Week Low
$2.25
52-Week Range
52 Week High
$5.14
2.25
1 Day
-
1 Week
-5.67%
1 month return
-4.77%
3 month return
-5.97%
6 month return
-36.91%
1 Year return
-18.3%
3 Years return
-39.83%
5 Years return
-64.98%
10 Years return
-
Institutional Holdings
Bvf Inc
19.73
BlackRock Inc
2.64
Redmile Group, LLC
1.71
Wells Fargo & Co
1.12
BlackRock Health Sciences Opps Inv A
1.09
Junked Platinum Investment Management Ltd
0.96
BlackRock Health Sciences Term Trust
0.79

Market Status

Fundamentals
Market Cap
308.7 mln
PB Ratio
2.09
PE Ratio
0
Enterprise Value
133.33 mln
Total Assets
182.81 mln
Volume

Company Financials

Fund house & investment objective

Company Information
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Organisation
AC IMMUNE SA
Employees
133
Industry
Biotechnology
CEO
Dr. Andrea  Pfeifer Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step